

**Regence BlueCross BlueShield of Oregon • Regence BlueShield
Regence BlueCross BlueShield of Utah • Regence BlueShield of Idaho
Independent licensees of the Blue Cross and Blue Shield Association**

Medication Policy Manual

Policy No: dru080

Topic: Antineoplaston Cancer Therapy

Date of Origin: November 1997

Revised/Effective Date: March 18, 2008

Next Review Date: March 2009

IMPORTANT REMINDER

This Medical Policy has been developed through consideration of medical necessity, generally accepted standards of medical practice, and review of medical literature and government approval status.

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.

The purpose of medical policy is to provide a guide to coverage. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care.

Description

Antineoplastons are described as mixtures of peptides, amino acid derivatives, and organic acids that are felt to possibly form a natural defense system against cancers and other diseases.

Policy/Criteria

Antineoplaston therapy is considered investigational for any indication.

Position Summary

- No antineoplaston product is approved for use by the U.S. Food and Drug Administration.
- No randomized controlled trial has demonstrated efficacy of antineoplastons.

References

1. Burzynski et al. Phase II clinical trials of antineoplaston A10 and AS2-1 infusions in astrocytoma. *Recent advances in chemotherapy*. 1991: 2506-2507.
2. Buckner et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. *Mayo Clinic Proceedings* 1999; 74: 137-145.
3. Green, S. Antineoplastons: an unproven therapy. *JAMA* 1992; 267:2924-2928.
4. Tsuda H et al. A novel strategy for remission induction and maintenance in cancer therapy. *Oncol Rep* 2002;9:65-8.
5. Burzynski SR, et al. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. *Integr Cancer Ther*. 2005 Jun;4(2):168-77.
6. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. *Integr Cancer Ther*. 2006;5:40.

Cross References
None

Codes	Number	Description
CPT	90784	Therapeutic IV infusion